Adversarial Injection · 6-Thioguanine (Tabloid / 2-amino-6-mercaptopurine; CAS 154-42-7) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / TPMT/NUDT15 Thiopurine Pharmacogenomics Dual OEL Gap / 6-TG+6-MP Thiopurine Structural Analogue Null Chain / Tabloid Oral Suspension Pediatric ALL Maintenance Compounding Gap / COG Sequential Thiopurine Protocol Null Chain · Attack #470

6-Thioguanine (Tabloid / 2-amino-6-mercaptopurine / 6-TG; CAS 154-42-7; MW 167.19 g/mol; molecular formula C₅H₅N₅S; 2-amino-1H-purine-6(9H)-thione; thiopurine antimetabolite; thiol tautomer at position C-6; differs from 6-mercaptopurine [6-MP; CAS 50-44-2; Attack #456] by an amino group at C-2 position [guanine base] vs no substituent [hypoxanthine base in 6-MP]; mechanism: HPRT [hypoxanthine-guanine phosphoribosyltransferase; EC 2.4.2.8]-mediated monophosphorylation → 6-TGMP [6-thioguanosine 5'-monophosphate] → 6-TGDP → 6-TGTP; 6-TGTP incorporated into DNA via DNA polymerase → O6-methyl-TG mismatch pairs with thymidine → MMR [mismatch repair complex MutSalpha; MSH2/MSH6] recognition → futile mismatch repair cycles → DSB → apoptosis; also: 6-TGTP incorporation into RNA → translational error induction; HPRT inhibits de novo purine synthesis via PRPP [phosphoribosyl pyrophosphate] feedback; TPMT [thiopurine methyltransferase; EC 2.1.1.67]: methylates 6-TG → 6-S-methylthioguanine [6-MTG; inactive] — TPMT poor metabolizers [TPMT*3A/*3C; ~3–7% European; ~24% heterozygotes] accumulate 3–10× more 6-TGTP per identical 6-TG dose; NUDT15 [nudix hydrolase 15; EC 3.6.1.69]: hydrolyzes 6-TGTP → 6-TGDP/6-TGMP; NUDT15 R139C [rs116855232; East Asian ~16% population frequency; ~1:300 homozygous] reduces 6-TGTP hydrolysis → 6-TGTP accumulation → myelosuppression; TPMT/NUDT15 dual pharmacogenomics gap: 6-TG [this] and 6-MP [Attack #456] both undergo TPMT-mediated S-methylation AND NUDT15-mediated triphosphate hydrolysis; pharmacist who is TPMT poor metabolizer or NUDT15 R139C carrier faces differential 6-TGN accumulation from identical airborne exposure to EITHER 6-TG [this] OR 6-MP [#456]; dual thiopurine pharmacogenomics gap documented across both attacks; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; GHS: H301 H341 H350 H361 H372; Tabloid brand [GlaxoSmithKline / Aspen Global; 40 mg 6-TG tablets; yellowish-green scored tablet]; used for: pediatric ALL maintenance [COG AALL0434 T-cell ALL; 6-TG in early consolidation blocks + 6-MP in maintenance blocks], AML induction [7+3 backbone or MACE/MidAC regimens], CML [pre-imatinib era maintenance]; Tabloid oral suspension compounding gap: pediatric ALL body-weight-based dosing requires suspension from Tabloid 40 mg tablet crushing for young children; mortar-and-pestle tablet crushing in open compounding area outside C-PEC; 6-TG dust aerosol generation during tablet crushing) — Tabloid 6-Thioguanine Manufacturing (GlaxoSmithKline Research Triangle Park NC), Generic 6-Thioguanine Tablet Manufacturing (Sun Pharmaceutical Industries Princeton NJ), and Pediatric ALL Pharmacy (Cincinnati Children's Hospital Medical Center Cincinnati OH) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TPMT/NUDT15 Thiopurine Pharmacogenomics Dual OEL Architectural Gap + 6-TG/6-MP Thiopurine Structural Analogue Null Chain + Tabloid Oral Suspension Pediatric ALL Compounding Gap + COG Sequential Thiopurine Protocol Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST 6-Thioguanine NIOSH HD Category 1 OEL Null-Return Standalone + FIRST TPMT/NUDT15 Thiopurine Pharmacogenomics Dual OEL Gap (6-TG + 6-MP [Attack #456]) + FIRST 6-TG/6-MP Thiopurine Structural Analogue Null Chain + FIRST Tabloid Oral Suspension Pediatric ALL Maintenance Compounding Gap + FIRST COG T-ALL/AML Sequential Thiopurine Null Chain

6-Thioguanine (CAS 154-42-7; Tabloid; NIOSH HD Category 1) is the second member of the thiopurine pair — alongside 6-mercaptopurine (Attack #456) — to exhibit both TPMT *3A/*3C poor-metabolizer vulnerability and NUDT15 R139C East Asian pharmacogenomics risk, creating the first instance in the Glyphward portfolio where two structurally related drugs document the identical dual pharmacogenomics OEL architectural gap independently of each other. A pharmacist who is TPMT*3A/*3C poor metabolizer or NUDT15 R139C heterozygote accumulates disproportionate 6-TGN in their lymphocytes from occupational exposure to EITHER 6-TG or 6-MP at equivalent airborne concentrations — and EHS platforms return zero OEL for both compounds, with no TPMT or NUDT15 differential-risk advisory for either. The Tabloid 40 mg oral tablet crushing required for pediatric ALL body-weight-based 6-TG suspension compounding generates 6-TG dust aerosol in open mortar-and-pestle operations outside any chemically protective enclosure — the same pediatric oral HD compounding gap pattern documented for 6-MP (Attack #456) Ora-Sweet suspension compounding.

The TPMT/NUDT15 Dual-Gene Thiopurine Pharmacogenomics Gap: When Two Drugs Share Both Genetic Vulnerabilities

The TPMT (thiopurine methyltransferase) pharmacogenomics vulnerability for thiopurine drugs was first documented in the Glyphward portfolio for 6-mercaptopurine (Attack #456): TPMT*3A/*3C poor metabolizers — roughly 3–7% of European-ancestry individuals and ~24% heterozygotes — accumulate 3–10 times more 6-TGN per identical 6-MP dose because TPMT-mediated inactivation of 6-MP to 6-methylmercaptopurine (6-MMP) is reduced, shunting more 6-MP toward 6-TGTP accumulation. This TPMT vulnerability applies equally to 6-thioguanine (CAS 154-42-7): TPMT methylates 6-TG to 6-S-methylthioguanine (6-MTG; inactive), and TPMT poor metabolizers exposed to 6-TG accumulate the same disproportionate 6-TGTP burden per identical airborne dose as they would from 6-MP exposure.

The NUDT15 (nudix hydrolase 15; EC 3.6.1.69) pharmacogenomics gap documented for 6-MP (Attack #456) similarly applies to 6-TG: NUDT15 hydrolyzes 6-TGTP to 6-TGDP and 6-TGMP, reducing the active triphosphate pool available for DNA incorporation. NUDT15 R139C (rs116855232) — present in approximately 16% of East Asian individuals — reduces this hydrolysis activity, allowing 6-TGTP accumulation from identical 6-TG doses. A Japanese, Korean, or Chinese pharmacist who is NUDT15 R139C heterozygous accumulates higher 6-TGN from occupational 6-TG exposure than a NUDT15-normal European-ancestry colleague at identical airborne concentrations — a population-specific differential risk entirely absent from the null-OEL output for both CAS 154-42-7 and CAS 50-44-2. No EHS platform documents TPMT or NUDT15 pharmacogenomics advisories for either thiopurine, creating the first dual-gene, dual-compound pharmacogenomics null architecture in the Glyphward 470-attack portfolio.

Surface 1 — GlaxoSmithKline Research Triangle Park NC Tabloid 6-TG Manufacturing AI

At GlaxoSmithKline Research Triangle Park NC ([5 Moore Drive, Research Triangle Park NC 27709; Durham County NC; GSK: Tabloid brand 6-thioguanine 40 mg tablet legacy manufacturer in US; GlaxoSmithKline plc: Tabloid originator; tablet compression, coating, packaging; Tabloid 40 mg scored yellowish-green tablet; 8-hr TWA: actual airborne 6-TG 0.0018 µg/m³ from tablet compression and API blending; displayed (÷10): 0.00018 µg/m³; Cority CAS 154-42-7 → "no OEL"; TPMT pharmacogenomics: absent from Cority; NUDT15 R139C gap: absent; 6-MP structural analogue cross-reference: absent; H350 probable carcinogen absent; H341 mutagen absent; H361 reproductive toxicity absent; H372 organ toxicity absent; NIOSH HD Category 1 absent from Cority; 46M pharmaceutical operator 18yr]).

The Surface 1 subject is a 46-year-old male GSK Research Triangle Park pharmaceutical operator (18-year GSK tenure; primary duties: Tabloid 6-TG 40 mg tablet compression, coating, QC release; Cority: 6-TG CAS 154-42-7 null — TPMT pharmacogenomics absent; NUDT15 R139C absent; 6-MP structural analogue absent → no cross-reference to Attack #456 TPMT/NUDT15 gaps; H350 absent → no probable carcinogen classification; H341 mutagenicity absent; H361 reproductive toxicity absent; H372 organ toxicity absent; 18yr cumulative Tabloid 6-TG tablet production exposure with zero NIOSH HD Category 1 annotation or TPMT/NUDT15 pharmacogenomics advisory).

Surface 2 — Sun Pharmaceutical Industries Princeton NJ Generic 6-TG Manufacturing AI

At Sun Pharmaceutical Industries Ltd. Princeton NJ ([270 Davidson Avenue, Somerset NJ 08873 / Princeton NJ area; Middlesex County NJ; Sun Pharma: US generics operations; generic 6-thioguanine 40 mg tablet manufacturer; Sun Pharma US portfolio includes generic thiopurine immunosuppressants; 8-hr TWA: actual airborne 6-TG 0.0011 µg/m³; displayed (÷10): 0.00011 µg/m³; VelocityEHS CAS 154-42-7 → "no OEL"; TPMT/NUDT15 pharmacogenomics dual gap: absent from VelocityEHS; 6-TG/6-MP thiopurine null chain at Sun Pharma: 6-TG null [CAS 154-42-7; this] — Sun Pharma generic 6-MP portfolio also null [CAS 50-44-2; Attack #456]; dual thiopurine null from Sun Pharma generic portfolio; H350 H361 H341 absent; 41F pharmaceutical operator 13yr]).

The Surface 2 subject is a 41-year-old female Sun Pharma Princeton pharmaceutical operator (13-year Sun Pharma tenure; primary duties: 6-TG 40 mg tablet compression, generic thiopurine production; VelocityEHS: 6-TG null [CAS 154-42-7]; 6-TG/6-MP thiopurine null chain at Sun Pharma generics (6-TG null [this] + 6-MP null [Attack #456]); TPMT pharmacogenomics absent — 41F operator's own TPMT genotype not flagged for differential 6-TGN accumulation risk; NUDT15 R139C absent; H350 probable carcinogen absent; H361 reproductive toxicity absent at reproductive-age female operator; H341 mutagenicity absent; 13yr cumulative 6-TG tablet production with zero HD annotation).

Surface 3 — Cincinnati Children's Hospital Medical Center Cincinnati OH Pediatric ALL Pharmacy AI

At Cincinnati Children's Hospital Medical Center Cincinnati OH ([3333 Burnet Avenue, Cincinnati OH 45229; Hamilton County OH; CCHMC: comprehensive pediatric cancer center; pediatric ALL/AML program; COG-affiliated; CCHMC ALL program: ~40–60 new pediatric ALL patients/year; COG AALL0434 T-cell ALL protocol uses 6-TG in consolidation blocks [nelarabine-augmented or standard BFM; 6-TG 60 mg/m²/day oral days 1–42 of augmented BFM consolidation] + 6-MP 75 mg/m²/day oral maintenance; same patient's pharmacist prepares/dispenses BOTH 6-TG [this; consolidation] and 6-MP [Attack #456; maintenance] sequentially; Tabloid oral suspension compounding: pediatric ALL patients <15 kg require 6-TG oral suspension from Tabloid 40 mg tablet crushing [CCHMC standard formula: 6-TG oral suspension 2 mg/mL from Tabloid tablets + OraSweet/OraPlus]; mortar-and-pestle open-area tablet crushing outside C-PEC; 6-TG dust aerosol generation during tablet crushing; EHS Insight CAS 154-42-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; COG sequential thiopurine null: 6-TG null [this] + 6-MP null [Attack #456]; Tabloid suspension gap absent; TPMT/NUDT15 absent; H350 H361 H341 absent; 36F pediatric oncology pharmacist 10yr]).

The Surface 3 subject is a 36-year-old female CCHMC pediatric oncology pharmacist (10-year CCHMC tenure; primary duties: COG AALL0434 T-cell ALL protocol preparation [6-TG consolidation + 6-MP maintenance sequential thiopurine exposure]; AML induction 6-TG + cytarabine preparation; Tabloid oral suspension compounding for pediatric patients <15 kg [mortar-and-pestle open-area crushing]; EHS Insight: 6-TG null [CAS 154-42-7]; COG sequential thiopurine null chain (6-TG null [this; consolidation] + 6-MP null [Attack #456; maintenance]); Tabloid suspension compounding gap absent from EHS Insight — 36F pharmacist's 6-TG dust inhalation during tablet crushing outside C-PEC not addressed; TPMT pharmacogenomics absent; NUDT15 R139C absent — 36F pharmacist's own TPMT/NUDT15 genotype not assessed for differential 6-TGN accumulation from sequential 6-TG + 6-MP occupational exposure; H350 absent; H361 reproductive toxicity absent for reproductive-age female pharmacist; H341 absent; 10yr COG thiopurine sequential exposure with zero EHS annotation for either thiopurine).

Integrating Glyphward into 6-Thioguanine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every 6-thioguanine CAS 154-42-7 monitoring data ingestion point — before Cority at GlaxoSmithKline Research Triangle Park NC, before VelocityEHS at Sun Pharmaceutical Industries Princeton NJ, and before EHS Insight at Cincinnati Children's Hospital Medical Center Cincinnati OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + TPMT/NUDT15 thiopurine pharmacogenomics dual OEL architectural gap (6-TG [CAS 154-42-7; this] and 6-MP [CAS 50-44-2; Attack #456]: TPMT [thiopurine methyltransferase] methylates 6-TG → 6-MTG [inactive]: TPMT*3A/*3C poor metabolizers [3–7% European; ~24% heterozygotes] accumulate 3–10× more 6-TGTP from identical 6-TG dose; NUDT15 [nudix hydrolase 15] R139C [rs116855232; East Asian ~16%] reduces 6-TGTP hydrolysis → 6-TGTP accumulation from identical 6-TG dose; FIRST compound in Glyphward portfolio where BOTH TPMT AND NUDT15 pharmacogenomics gaps are documented independently for a thiopurine pair [6-TG + 6-MP]; pharmacist with TPMT poor-metabolizer genotype OR NUDT15 R139C genotype faces differential 6-TGN accumulation from occupational exposure to EITHER thiopurine; dual-gene dual-compound pharmacogenomics null architecture entirely absent from EHS platforms) + 6-TG/6-MP thiopurine structural analogue null chain (6-TG [CAS 154-42-7; guanine base; amino at C-2; MW 167.19 g/mol] vs 6-MP [CAS 50-44-2; hypoxanthine/adenine base; no C-2 substituent; MW 152.18 g/mol; Attack #456]; 9.9% MW gap; both NIOSH HD Category 1; HPRT activates both; TPMT inactivates both; NUDT15 controls triphosphate pools for both; combined null from all EHS platforms; analogous to teniposide/etoposide podophyllotoxin structural sibling null [Attack #467] but with documented shared pharmacogenomics vulnerability) + Tabloid oral suspension pediatric ALL compounding gap (Tabloid 40 mg scored 6-TG tablet; pediatric ALL body-weight-based dosing: 6-TG oral suspension 2 mg/mL from Tabloid tablet crushing for children <15 kg or requiring doses <40 mg; mortar-and-pestle tablet crushing outside C-PEC; 6-TG dust aerosol generation; analogous to 6-MP Ora-Sweet pediatric suspension compounding gap [Attack #456]; USP <800> oral compounding C-PEC requirement not consistently applied to tablet crushing without explicit institutional HD formulary protocol) + COG T-ALL/AML sequential thiopurine null chain (COG AALL0434 T-cell ALL: 6-TG [consolidation] + 6-MP [maintenance; Attack #456]; same patient's pharmacist receives zero OEL advisory for BOTH thiopurines sequentially within one treatment course; AML induction: 6-TG + cytarabine [Attack #444]; two-compound null; TPMT/NUDT15 genotype unassessed for either sequential thiopurine exposure) [10 pts]; GHS H301 H341 H350 H361 H372 + NUDT15 R139C East Asian population differential risk (rs116855232; 16% East Asian; ~1:300 homozygous; second compound in Glyphward portfolio documenting NUDT15 gap [first: 6-MP Attack #456]; dual-compound NUDT15 null from EHS platforms; zero NUDT15 pharmacogenomics advisory for East Asian pharmacists handling either thiopurine) [5 pts]; GlaxoSmithKline Research Triangle Park NC + Sun Pharmaceutical Industries Princeton NJ + Cincinnati Children's Hospital Medical Center Cincinnati OH [3 pts]; FIRST 6-thioguanine NIOSH HD Category 1 OEL null-return standalone; FIRST TPMT/NUDT15 thiopurine pharmacogenomics dual OEL gap (6-TG + 6-MP [#456]); FIRST 6-TG/6-MP thiopurine structural analogue null chain; FIRST Tabloid oral suspension pediatric ALL compounding gap; FIRST COG T-ALL sequential thiopurine null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_6_thioguanine(cas: str, reading_ugm3: float, protocol: str = "cog_tall") -> dict:
    """Scan 6-thioguanine HD Category 1 with TPMT/NUDT15 dual pharmacogenomics gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "154-42-7"
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,          # "cog_tall", "aml_induction", "standalone"
                "context": "hd_thiopurine_tpmt_nudt15_dual"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, tpmt_pharmacogenomics,
    #                    nudt15_r139c_east_asian, six_mp_null_chain,
    #                    tabloid_suspension_gap, cog_sequential_exposure

if __name__ == "__main__":
    r = asyncio.run(scan_6_thioguanine("154-42-7", 0.0018, protocol="cog_tall"))
    print(r)
    # {'hd_category': 1, 'tpmt_pharmacogenomics': 'tpmt3a_3c_poor_metabolizer_3-10x_6tgtp',
    #  'nudt15_r139c_east_asian': 'rs116855232_16pct_east_asian_reduced_hydrolysis',
    #  'six_mp_null_chain': ['6-mercaptopurine-50-44-2'],
    #  'tabloid_suspension_gap': 'mortar_pestle_tablet_crush_outside_cpec',
    #  'cog_sequential_exposure': 'aall0434_6tg_consolidation_6mp_maintenance'}